Group items tagged

A contrast agent (also called a contrast medium) is an electrically charged material used in medical imaging to enhance the contrast of medical vessels or other tissues in the body. Contrast media/contrast agent either absorbs or changes ultrasound or electromagnetism, which is fundamentally different from radiopharms, which themselves emit electromagnetic radiation. This difference enables contrast agents to be applied to various body tissues with much higher strengths than their non-comp contrast counterparts. The most common contrast media/contrast agent used in medical imaging are CT contrast agents and MRI contrast agents. However, due to their non-magnetic nature, these medical imaging products are not able to be used on organ tissues, such as kidneys, hearts and lungs. Some manufacturers have now started manufacturing non-magnetic, biologically engineered CT and MRI contrast agents called mri-notherapy (mammography, radiofrequency ablation, and ultrasound contrast agents). High prevalence of cancer is expected to boost demand for contrast media. In the U.S., non-magnetic, biologically engineered CT and MRI contrast agents are now being used more frequently to treat patients with benign tumors of all types. Mri-notherapy is used for benign cancers of the breast (breast cancer), abdomen (belly fat), neck, head, joint (arthritis) and spine. Patients with melanoma, anemia, inoperable basilar artery disease, and multiple myeloma are also often treated with mri-notherapy. The therapy has a high success rate for benign tumors and very low incidence of mortality, espeacially in patients undergoing surgery. Moreover, recently, in November 2020, the U.S. FDA approved GE Healthcare's macrocyclic gadolinium-based MRI contrast agent, Clariscan (gadoterate meglumine), in pre-filled syringes. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/high-prevalence-of-cancer-to-boost.html

How chemotherapy takes place? Depending on type of cancer and period of cancer, it stops cancer cells ability of damage and more to divide. Oftenly drugs are used and different for different person. This is systematic therapy also affect your entire body.

Patients who are suffering from cancer receive Chemotherapy often suffer treatment side effects including fatigue, sleep disturbances, and other physical and mental side effects. Amongst all, Sleep disturbance is the most common symptoms which are experienced by cancer patients, occurs in approx. 80% of patients during chemotherapy, and results in hindering in quality of life. Several studies have researched the effectiveness of yoga, which includes breathing, postures, and/or meditation, in a population of patients with cancer.

Diagnosing Cancer at its earliest stages usually provides the most effective probability for a cure. The days - or even weeks - spent waiting for the results of a cancer-screening test can feel like perpetuity. Especially when the early diagnosis and treatment are tied to better outcomes. Now, a new technique to analyze proteins implemented on cancer cells shows promise in rapidly detecting these cell types.

The multi-specialty hospitals in India are best regarded in treating prostate cancer surgery in India which can be equipped with a competent team of exceptional pancreatic cancers surgeons and hospitals

Head & neck cancers include a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands, and mouth. There are different types of drugs used alone or in combination for treatment of head & neck cancer. Although traditional chemotherapeutic drugs preferably used in combination of radiation therapy, targeted immune therapies are emerging as a standard treatment option for advanced-stage head & neck cancers.

Head & neck cancers include a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands, and mouth. There are different types of drugs used alone or in combination for treatment of head & neck cancer. Although traditional chemotherapeutic drugs preferably used in combination of radiation therapy, targeted immune therapies are emerging as a standard treatment option for advanced-stage head & neck cancers.

"""Pancreatic Cancer Drug Pipeline Analysis""Pancreatic Cancer Drug Pipeline Analysis" by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Pancreatic Cancer. "

Launch of new products is expected to propel growth of the metabolomics market. For instance, in January 2021, JUNO Metabolomics launched the JUNO Viral Surveillance Platform based on its proprietary AI-Based Informatics System. Similarly, in June 2019, Bruker Corp. presented mass spectrometry and Nuclear Magnetic Resonance systems and other solutions for molecular phenomics and clinical metabolomics research at Metabolomics 2019. Moreover, increasing prevalence of chronic disorders is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S. Integration of Artificial Intelligence (AI) with metabolomics is expected to offer lucrative growth opportunities for players in the metabolomics market. For instance, in July 2020, ReviveMed, an AI-driven drug discovery platform, collaborated with Bristol Myers Squibb for an AI-driven metabolomics study that will leverage ReviveMed's AI platform to better understand mechanisms of response and resistance to immunotherapies in patients with cancer. Moreover, increasing demand for metabolomics is also expected to aid in growth of the market. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/integration-of-ai-with-metabolomics-and.html

Opioid-induced constipation (OIC) is caused by prolonged use of certain opioids, particularly for pain management. OIC may also be caused by taking long-term and excessive doses of narcotics with effects similar to dehydration, constipation, or nausea. OIC is a common condition affecting individuals with long-standing or steady use of powerful prescription pain medications like OxyContin, codeine and morphine, as well as individuals who take sedatives frequently or individuals who have other conditions like diarrhea, kidney or liver disease, or Crohn's disease. Approval and launch of new products is expected to propel growth of the Opioid Induced Constipation Treatment Market. For instance, in September 2020, Sandoz, the generics division of Novartis AG, received a positive reimbursement decision in the UK for Rizmoic (naldemedine). The National Institute for Health and Care Excellence, U.K., issued a recommendation in favor of the option for treating opioid-induced constipation in adults, after previous laxative treatment. Moreover, high prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/approval-and-launch-of-new-products-and.html

PET-CT Scanner devices are highly advanced devices that help physicians make a correct diagnosis of the disease earlier, reducing unnecessary suffering to patients. They are widely used in a number of applications in the healthcare industry. One such medical application is in the field of diagnosing certain diseases, wherein the scanning of the body tissues, the positron emission tomography or PET-CT is used as a diagnostic tool. By using the ionization technique, scientists are able to locate and map the location of the abnormalities in a patient's body. This technology is a boon to mankind as it has helped in reducing the number of deaths caused by various diseases due to their early detection. The growing prevalence of cancer, HIV, and cardiovascular disease is driving the PET-CT scanner device market growth. Out of these chronic diseases, cancer held the highest share in the market. According to the World Health Organization, cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. According to the U.S. Department of Health & Human Services, an estimated 36,400 new HIV infections occurred in the United States in 2018. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/pet-ct-scanner-devices-gaining-traction.html

Know what is Gallbladder Cancer. Find out symptoms, causes and treatment of Gallbladder Cancer by the oncologists in Apollo Hospitals Mumbai.

All about lung cancer, causes risk factors, by Fostr multispeciality clinic. Lung cancer often has more particular symptoms until its advanced and has low rate of survival.

What are oral cancer symptoms? What is the treatment for Oral cancer and how to prevent oral cancer.

Lung biopsy helps in detecting the stages of cancerin patients;thus, increasing the demand for biopsies across the world as it is an important tool for diagnosis and treatment. Biopsy followed by imaging tests helps in determining whether the nodule is cancerous or non-cancerous. As per WHO, in 2018, lung cancer is responsible for the largest number of deaths approximately 1.8 million deaths across the globe because of the poor prognosis for this cancer. Lower respiratory infections remained the deadliest communicable disease, causing 3.0 million deaths worldwide in 2016.

Ovarian Cancer Pipeline Analysis" by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Ovarian Cancer. Research report covers all the ongoing drug development in various phases.

Surgery Tours India we provide Leukemia (Blood cancer) Treatment at Low Cost & at Top Leukemia Treatment Hospital in India. EMAIL US for FREE QUOTE & get Leukemia (Blood cancer) Treatment.

Prevalence of cancer is on the rise throughout the world. Advanced therapeutics are being developed by pharmaceutical companies to address the growing burden of cancer. The time and costs associated with oncology drug development are also increasing; hence the key companies are collaborating with other pharmaceutical companies to reduce these costs.